MENLO PARK, Calif.--(BUSINESS WIRE)--Jan 11, 2021--
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today confirmed it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021.
In December, GRAIL completed the
"We are encouraged by the significant early interest in Galleri from health systems, medical practices, and self-insured employers."
